Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
Identificadores
URI: http://hdl.handle.net/10481/55557Metadata
Show full item recordEditorial
Universidad de Granada, Facultad de Farmacia
Materia
antibodies monoclonal breast neoplasms Trastuzumab Drug-Related Side Effects Adverse Reactions Medical Oncology
Date
2017Referencia bibliográfica
Iago Dillion Lima Cavalcanti, Analúcia Guedes Silveira Cabral, Rosiel José dos Santos. Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer. Ars Pharm, 58(4): 171-174 (2017)
Abstract
Objective: identify the main adverse reactions presented by patients with HER2 positive breast cancer
from an outpatient clinic specialized in chemotherapy in the city of Caruaru-PE, after the use of Trastuzumab.
Methods: The data were obtained through the analysis of the medical records of the patients attended at
the outpatient clinic from January 2015 to December 2016.
Results: Twenty-four patients were selected, of whom 12.5% presented cardiotoxicity and 4.16% presented
abdominal pain, nausea among other adverse events.
Conclusion: Identifying such adverse events makes it possible to better assist the oncological patient
and to better adhesion to the treatment. Because they are specific target drugs, few studies are concerned
with evaluating these adverse events, which often makes clinical care difficult. Objetivo: identificar las principales reacciones adversas presentadas por pacientes con cáncer de mama
HER2 positivo desde una clínica ambulatoria especializada en quimioterapia en la ciudad de Caruaru-
PE (Brasil), después del uso de Trastuzumab.
Métodos: los datos se obtuvieron mediante el análisis de los registros médicos de los pacientes atendidos
en la consulta externa entre enero de 2015 y diciembre de 2016.
Resultados: se seleccionaron 24 pacientes, de los cuales 12.5% presentaron cardiotoxicidad y 4.16% presentaron
dolor abdominal, náuseas entre otros eventos adversos.
Conclusión: la identificación de tales eventos adversos permite una mejor asistencia al paciente oncológico
y una mejor adhesión al tratamiento. Debido a que son medicamentos específicos, pocos estudios
se preocupan por evaluar estos efectos adversos, lo que a menudo dificulta la atención clínica.